Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 70Breast Neoplasms 52Ovarian Neoplasms 43Lung Neoplasms 24Neoplasms 21Neoplasm Metastasis 20Fallopian Tube Neoplasms 20Carcinoma, Ovarian Epithelial 18Triple Negative Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Head and Neck Neoplasms 9Stomach Neoplasms 8Recurrence 8Endometrial Neoplasms 8Adenocarcinoma of Lung 8Melanoma 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 5Uterine Neoplasms 4Solid Tumors 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma Of Esophagus 4Thoracic Neoplasms 3Testicular Neoplasms 3Solid Tumor 3Sarcoma 3

Interventions

exemestane 1Paclitaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × First Line Metastatic Breast Cancer × Paclitaxel × Clear all
NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

ARCAGY/ GINECO GROUP

Phase 3 Terminated
117 enrolled
Breast

First Line Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡